CST, 3219S, TRAIL (C92B9) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying Trail. Validated for WB,WB,IP,IHC,IF,F,F. Available in 2 sizes. Highly specific and rigorously validated in-house, TRAIL (C92B9) Rabbit Monoclonal Antibody (CST #3219) is ready to ship. Product Usage Information Western Blotting: 1:1000 Simple Western™: 1:10 - 1:50 Immunoprecipitation: 1:50 Immunohistochemistry (Paraffin): 1:800 Immunofluorescence (Immunocytochemistry): 1:400 Flow Cytometry (Fixed/Permeabilized): 1:50 Flow Cytometry (Live): 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. For a carrier free (BSA and azide free) version of this product see product # 48318 . Protocol Available protocols: Western Blotting, Immunoprecipitation, Immunohistochemistry (Paraffin), Immunofluorescence (Immunocytochemistry), Flow Cytometry (Fixed/Permeabilized), Flow Cytometry (Live) Specificity / Sensitivity TRAIL (C92B9) Rabbit Monoclonal Antibody detects endogenous levels of total human TRAIL protein. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Lys60 of human TRAIL, within the extracellular region of the protein. Background Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also referred to as Apo2 ligand, first identified based on its sequence homology to TNF and Fas/Apo ligand is a member of the TNF family of cytokines and either exists as a type II membrane or soluble protein (1,2). TRAIL induces apoptosis in a variety of transformed cell lines and plays a role in anti-tumor and anti-viral immune surveillance (3). TRAIL signals via binding with death receptors DR4 (TRAIL-R1) (4) and DR5 (TRAIL-R2) (5-8) which can trigger apoptosis as well as NF-κB activation (7,9). Death domains on these receptors leads to the recruitment of a death-induced signaling complex (DISC) leading to caspase-8 and subsequent caspase-3 activation. In addition, TRAIL binds with decoy receptors DcR1 (TRAIL-R3) (6,8,10,11) and DcR2 (TRAIL-R4, TRUNDD) (12,13) which lack the functional cytoplasmic death domain antagonizing TRAIL-induced apoptosis. Osteoprotegerin (OPG) has also been identified as receptor capable of inhibiting TRAIL-induced apoptosis (14). The selectivity of soluble TRAIL at triggering apoptosis in transformed cells as compared to normal cells has led to its investigation as a potential cancer therapeutic (15,16). Alternate Names Apo-2 ligand; Apo-2L; APO2L; CD253; chemokine tumor necrosis factor ligand superfamily member 10; Protein TRAIL; TL2; TNF superfamily member 10; TNF-related apoptosis inducing ligand TRAIL; TNF-related apoptosis-inducing ligand; TNF10; TNFSF10; TNLG6A; TRAIL; tumor necrosis factor (ligand) family, member 10; tumor necrosis factor (ligand) superfamily, member 10; tumor necrosis factor apoptosis-inducing ligand splice variant delta; tumor necrosis factor ligand 6A; Tumor necrosis factor ligand superfamily member 10; tumor necrosis factor superfamily member 10 Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 28-30 Source/Isotype: Rabbit IgG